It's that time of year again. The nip in the air is almost gone; the birds have returned from their southern haunts, and madness grips the nation as men, women, and children suddenly grapple with one of spring's deepest mysteries: NCAA brackets.
EUSA/Cytogen: Two-year old spec pharma EUSA Pharma continued pursuit of its rapid product- and infrastructure-build-up this week with the $22.6 million cash acquisition of US oncology and pain control group Cytogen Corp. EUSA—whose ambition is to become the next Shire—spotted a good moment to buy the ailing US group, whose shares have fallen steadily since early 2007, in part due to poorly-focused management. (See this IN VIVO Blog post for more.) Unlike most other spec pharma, EUSA’s goal has been to establish from the outset a business in Europe and in the US (as its name suggests). A tall order for a start-up, perhaps, but one that allows it to access a wider pool of product opportunities, larger growth potential, and to avoid the trap that many other European spec pharma hopefuls have fallen into: lack of focus. (See this IN VIVO feature for more background.)